Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2Completed 2Active not recruiting 2Unknown 1Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Classical hematology 1

Conditions

Multiple Myeloma 20Lymphoma 17Neoplasm Metastasis 14Leukemia, Myeloid, Acute 12Pancreatic Neoplasms 9Breast Neoplasms 9Ovarian Neoplasms 8Melanoma 8Lung Neoplasms 8Colorectal Neoplasms 8Sarcoma 7Prostatic Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 7Glioma 7Fallopian Tube Neoplasms 7Cholangiocarcinoma 7Neuroblastoma 6Lymphoma, Non-Hodgkin 6Lymphoma, Follicular 6Endometrial Neoplasms 6Lymphoma, Large B-Cell, Diffuse 5Ependymoma 5Burkitt Lymphoma 5Wilms Tumor 4Urinary Bladder Neoplasms 4Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Rhabdomyosarcoma 4Rhabdoid Tumor 4Neuroectodermal Tumors, Primitive, Peripheral 4

Interventions

fludarabine phosphate 2fludarabine 2Tacrolimus 2Specimen Handling 2Mycophenolic Acid 2Cyclophosphamide 2Busulfan 2Biopsy 2venetoclax 1veliparib 1tagraxofusp 1decitabine and cedazuridine drug combination 1Whole-Body Irradiation 1Topotecan 1Thiotepa 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1Melphalan 1Injections 1Idarubicin 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Decitabine 1Cytarabine 1Cyclosporine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Myelodysplastic-Myeloproliferative Diseases × Biopsy × Clear all
NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT06034470 2026-05-07

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Fred Hutchinson Cancer Center

Phase 1 Active not recruiting
30 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡